「company:"Johnson & Johnson"」に一致するピン

Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.

Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.

North Carolina Governor Josh Stein announced that Johnson & Johnson will build a second multibillion-dollar plant in Wilson, a drug product manufacturing facility for cancer and neurology medicines expected to create up to 500 jobs, beside the $2 billion biologics campus it is already building there.

The FDA approved Johnson & Johnson's Icotyde (icotrokinra), a once-daily pill and the first targeted oral peptide to block the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and children 12 and older weighing at least 40 kg.

Johnson & Johnson reported second-quarter sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, and raised its 2026 outlook to about $101.1 billion in sales and $11.68 adjusted EPS at the midpoint.

Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.

Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.

Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.

Johnson & Johnson reported positive topline results from Study 451: once-daily Caplyta (lumateperone) 42 mg cut manic symptoms in bipolar I disorder by 4.8 YMRS points more than placebo at week 3, with a significant effect from day 3.

Johnson & Johnson releases its third-quarter 2026 results at about 6:45 a.m. Eastern on Tuesday 13 October and reviews them on an 8:30 a.m. investor call hosted by CEO Joaquin Duato and CFO Joseph Wolk.

Johnson & Johnson holds its first enterprise business review since December 2023, where CFO Joseph Wolk says it will set out growth above its 5% to 7% long-term target, with a clear line of sight to double digits by the end of the decade.

Johnson & Johnson's orthopaedics business is due to leave the group as DePuy Synthes - by tax-free spinoff or by sale, with Apollo in talks at about $20 billion - and J&J says it is on track for a mid-2027 separation.